WASHINGTON, DC – The Center for Laser Surgery, Washington, DC has announced the availability of Dysport, abobotulinum toxin-A. Dysport, recently FDA approved, is the first cosmetic neurotoxin available alongside the widely used BOTOX® Cosmetic (botulinum toxin-A).
The Center for Laser Surgery was principal investigator of the FDA Stage III Clinical Trials for Dysport. As Washington, DC, Maryland and Virginia's largest and most experienced Botox practice, the center was honored to be the sole Dysport investigator in DC.
Dysport is a simple, effective, non-surgical treatment that works by relaxing facial muscles, thereby reducing and smoothing away frown-lines and wrinkles. Dysport, like Botox, is a protein extracted from the bacterium Clostridium Botulinum. Dysport has been available in Europe, Asia and South America for over 10 years. Dysport is manufactured by Ipsen Pharmaceuticals (FRA) and distributed in the United States by Medicis, manufacturer of the Restylane dermal filler.
Many cosmetic physicians outside the U.S. who have used Dysport report faster action and greater longevity for Dysport when compared to Botox. In most unbiased neurological studies for the treatment of movement disorders, Dysport has provided equal or greater efficacy when used in a 2.5 to 4:1 ratio to Botox. In a double-blinded randomized crossover study in cervical dystonia (the most common use of neurotoxins in the world), results showed Dysport to be more effective than Botox with a similar safety and side effect profile when used in a 3:1 dose relationship.
In 2006, Dr. Robert M. Adrian, founder of the Center for Laser Surgery, sponsored and fully funded a 24-patient double blinded comparative study of Dysport and Botox in the treatment of forehead lines in Karlsruhe, Germany. The results of this independent study, both physical observation and patient feedback, indicated that Dysport was faster acting with equal or greater longevity than Botox when used in a 3:1 unit ratio to Botox.
